Svein Inge Helle

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations

Medicine, Nuclear Medicine, Radiation Oncology +17

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

Oliver Sartor, Robert L. Coleman, Sten Nilsson et al. · The Lancet Oncology · 2014 · 491 citations

Medicine, Oncology, Pharmacology +17

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

Peter Hoskin, Oliver Sartor, Joe M. O’Sullivan et al. · The Lancet Oncology · 2014 · 407 citations

Medicine, Oncology, Pharmacology +17

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

Oliver Sartor, Robert E. Coleman, Sten Nilsson et al. · Annals of Oncology · 2017 · 169 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

Christopher Parker, Robert E. Coleman, Oliver Sartor et al. · European Urology · 2017 · 106 citations · Full text

Medicine, Oncology, Radiation Oncology +17